Drug intelligence / Profile preview

MEN2602

Development stage: Preclinical
Lead developer: Menarini

Overview

MEN2602 is an investigational biologic agent currently in the preclinical stage of development by A. Menarini (Menarini Group). It is being explored for the treatment of multiple tumor types. While the specific molecular target and mechanism of action have not been publicly disclosed, the asset is a key component of Menarini's early-stage oncology portfolio, which emphasizes the development of targeted biological therapies for cancer.

Beyond the preview

Go deeper on MEN2602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEN2602.

Explore the full profile